{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:20:26Z","timestamp":1780572026637,"version":"3.54.1"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RC2019.1.6_ROSSI"],"award-info":[{"award-number":["RC2019.1.6_ROSSI"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Eosinophilic oesophagitis is a long-term complication of oesophageal atresia (EA), an uncommon condition that affects approximately 1 in 3500 infants. An exploratory, open-label phase 2 clinical trial was conducted in paediatric eosinophilic oesophagitis after oesophageal atresia (EoE-EA) to assess the safety, pharmacokinetics, and efficacy of oral viscous budesonide (OVB). In total, eight patients were enrolled in the study and assigned to a twice-daily dosing regimen of either 0.8 or 1 mg OVB, depending on age and height, administered for 12 weeks. OVB was safe and effective in the treatment of EoE-EA. The current investigation focuses on the pharmacokinetics of budesonide and the impact of an oral viscous formulation on its absorption and bioavailability. Using a non-linear mixed effects approach, two distinct absorption profiles were identified, despite marked interindividual variability in drug concentrations. Budesonide exposure was higher than previously reported in children following oral inhalation. Even though no significant effect has been observed on serum cortisol levels, future studies should consider exploring different doses, schedules, and\/or treatment durations, as there may be an opportunity to reduce the risk of cortisol suppression.<\/jats:p>","DOI":"10.3390\/pharmaceutics16070872","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:04:18Z","timestamp":1719986658000},"page":"872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetic Evaluation of Oral Viscous Budesonide in Paediatric Patients with Eosinophilic Oesophagitis in Repaired Oesophageal Atresia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7703","authenticated-orcid":false,"given":"Raffaele","family":"Simeoli","sequence":"first","affiliation":[{"name":"Division of Metabolic Diseases, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-5462","authenticated-orcid":false,"given":"Sebastiano A. G.","family":"Lava","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Therapeutics Group, University College London, London WC1N 3JH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Deo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Therapeutics Group, University College London, London WC1N 3JH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-033X","authenticated-orcid":false,"given":"Marco","family":"Roversi","sequence":"additional","affiliation":[{"name":"PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5925-0974","authenticated-orcid":false,"given":"Sara","family":"Cairoli","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Tambucci","sequence":"additional","affiliation":[{"name":"Digestive Endoscopy Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rea","sequence":"additional","affiliation":[{"name":"Digestive Endoscopy Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Malamisura","sequence":"additional","affiliation":[{"name":"Digestive Endoscopy Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8719-9670","authenticated-orcid":false,"given":"Giulia","family":"Angelino","sequence":"additional","affiliation":[{"name":"Digestive Endoscopy Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Biondi","sequence":"additional","affiliation":[{"name":"Centre of Excellence for the Development and Implementation of Medicines, Vaccines, and Medical Devices for Pediatric Use, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Centre of Excellence for the Development and Implementation of Medicines, Vaccines, and Medical Devices for Pediatric Use, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Digestive Endoscopy Unit, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-3379","authenticated-orcid":false,"given":"Carlo","family":"Dionisi Vici","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-7918","authenticated-orcid":false,"given":"Paolo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Centre of Excellence for the Development and Implementation of Medicines, Vaccines, and Medical Devices for Pediatric Use, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pontrelli","sequence":"additional","affiliation":[{"name":"Centre of Excellence for the Development and Implementation of Medicines, Vaccines, and Medical Devices for Pediatric Use, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6211-1430","authenticated-orcid":false,"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Therapeutics Group, University College London, London WC1N 3JH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Goffredo","sequence":"additional","affiliation":[{"name":"Division of Metabolic Diseases, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,28]]},"reference":[{"key":"ref_1","first-page":"545","article-title":"Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: Review of genetics and epidemiology","volume":"43","year":"2006","journal-title":"J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/a-2206-6837","article-title":"The French Experience with a Population-Based Esophageal Atresia Registry (RENATO)","volume":"34","author":"Sfeir","year":"2024","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/MPG.0000000000001401","article-title":"ESPGHAN-NASPGHAN Guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with esophageal atresia-tracheoesophageal fistula","volume":"63","author":"Krishnan","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000350400","article-title":"Esophagitis with eosinophil infiltration associated with congenital esophageal atresia and stenosis","volume":"161","author":"Yamada","year":"2013","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0035-1559815","article-title":"Eosinophilic esophagitis in children with esophageal atresia","volume":"25","author":"Krishnan","year":"2015","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jaci.2018.08.040","article-title":"Analysis of eosinophilic esophagitis in children with repaired congenital esophageal atresia","volume":"143","author":"Krishnan","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/dote.12119","article-title":"Eosinophilic esophagitis in children with esophageal atresia","volume":"27","author":"Dhaliwal","year":"2014","journal-title":"Dis. Esophagus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0038-1676505","article-title":"Prevalence and predictive factors of histopathological complications in children with esophageal atresia","volume":"29","author":"Petit","year":"2019","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MPG.0000000000002261","article-title":"Prevalence of eosinophilic esophagitis in adolescents with esophageal atresia","volume":"69","author":"Lardenois","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100116","DOI":"10.1016\/j.waojou.2020.100116","article-title":"Eosinophilic esophagitis in esophageal atresia: Tertiary care experience of a \u201cselective\u201d approach for biopsy sampling","volume":"13","author":"Tambucci","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MPG.0000000000002336","article-title":"Esophagitis in pediatric esophageal atresia: Acid may not always be the issue","volume":"69","author":"Yasuda","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: Results from a phase 3 trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2040622310379293","article-title":"Therapeutic benefits of budesonide in gastroenterology","volume":"1","year":"2010","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bcp.14406","article-title":"Therapeutic index of inhaled corticosteroids in asthma: A dose-response comparison on airway hyperresponsiveness and adrenal axis suppression","volume":"87","author":"Brealey","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40268-020-00324-1","article-title":"A Pharmacokinetic bridging study to compare systemic exposure to budesonide between budesonide oral suspension and ENTOCORT EC in healthy individuals","volume":"20","author":"Song","year":"2020","journal-title":"Drugs R&D"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MPG.0000000000003482","article-title":"Pharmacokinetics of budesonide oral suspension in children and adolescents with eosinophilic esophagitis","volume":"75","author":"Gupta","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/MPG.0000000000003830","article-title":"Oral viscous budesonide in children with eosinophilic esophagitis after repaired esophageal atresia: A clinical trial","volume":"77","author":"Tambucci","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.2009.03591.x","article-title":"What is the right dose for children?","volume":"70","author":"Cella","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00228-010-0974-3","article-title":"Modelling and simulation as research tools in paediatric drug development","volume":"67","author":"Bellanti","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_22","first-page":"83","article-title":"Pediatric gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Guideline Executive summary","volume":"49","author":"Tringali","year":"2017","journal-title":"Endoscopy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis","volume":"13","author":"Gupta","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.17554\/j.issn.2224-3992.2018.07.750","article-title":"Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis","volume":"7","author":"Reed","year":"2018","journal-title":"HSOA J. Gastroenterol. Hepatol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared with Placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2007.01379.x","article-title":"Oral viscous budesonide: A potential new therapy for eosinophilic esophagitis in children","volume":"102","author":"Aceves","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_28","unstructured":"(2022, September 25). The ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis. 25 July 2022 EMA\/CHMP\/ICH\/172948\/2019, Committee for Medicinal Products for Human Use. Available online: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/j.ejps.2017.05.032","article-title":"Population pharmacokinetics of NNZ-2566 in healthy subjects","volume":"109S","author":"Oosterholt","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pupt.2017.12.002","article-title":"On the pharmacokinetics of two inhaled budesonide\/formoterol combinations in asthma patients using modeling approaches","volume":"48","author":"Soulele","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bcp.12322","article-title":"Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research","volume":"78","author":"Piana","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.clinthera.2004.11.017","article-title":"Relationship between systemic corticosteroid exposure and growth velocity: Development and validation of a pharmacokinetic\/pharmacodynamic model","volume":"26","author":"Richards","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_33","unstructured":"R Core Team (2022). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_34","first-page":"803","article-title":"Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn\u2019s disease","volume":"43","author":"Andersson","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1080\/14656566.2016.1183648","article-title":"Budesonide for the treatment of ulcerative colitis","volume":"17","author":"Abdalla","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Back, H.M., Lee, J.B., Kim, A., Park, S.J., Kim, J., Chae, J.W., Sheen, S.S., Kagan, L., Park, H.S., and Ye, Y.M. (2020). Exposure-response and clinical outcome modeling of inhaled budesonide\/formoterol combination in asthma patients. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12040336"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clinthera.2019.03.007","article-title":"Pharmacokinetics and tolerability of budesonide\/glycopyrronium\/formoterol fumarate dihydrate and glycopyrronium\/formoterol fumarate dihydrate metered dose inhalers in healthy Chinese adults: A randomized, double-blind, parallel-group study","volume":"41","author":"Chen","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.rmed.2005.11.020","article-title":"Systemic side effects of inhaled corticosteroids in patients with asthma","volume":"100","author":"Dahl","year":"2006","journal-title":"Respir. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00003088-200140060-00004","article-title":"Clinical pharmacokinetics of inhaled budesonide","volume":"40","author":"Donnelly","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.mex.2016.02.004","article-title":"An LC-MS\/MS method for the determination of budesonide and 16\u03b1-hydroxyprednisolone in dog plasma","volume":"3","author":"Gazzotti","year":"2016","journal-title":"MethodsX"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/7\/872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:28Z","timestamp":1760108848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/7\/872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["pharmaceutics16070872"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16070872","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}